General discussion, page-16934

worth noting they were trading between 42-52c in the lead up to the sale. Shareholders getting a premium on trading price of 75c (us) per share held.
So to put into perspective what vinnys said and add say a 10-20% premium into it I reckon, in regards to value. And this is just our psi-gad arm.
If 42x
675A
216A
even get close to phase 3 and offers come in, one can start putting all that into perspective, let alone any of the above reaching FDA approval for commercialisation. Yes we are talking about a pre clinical buyout but it just shows the appetite for this field and we are one of the more advanced with clinics about to be rolled out to set a standard/blueprint for worldwide application in a more streamlined manner as we will be the Guinea pigs for pros and cons and what worked and didn’t. bloody scary stuff when you start thinking of it on a individual drug arm let alone combinations.
It’s this reason i’m all in for the nasdaq.

Gltah